Quabodepistat-d7

Quabodepistat-d7 (OPC-167832-d7) is deuterium labeled Quabodepistat. Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with?an IC50 of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis?caused by?Mycobacterium tuberculosis[1].

Product Specifications

Product Name Alternative

OPC-167832-d7

UNSPSC

12352101

Target

Bacterial; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C1NC2=C(C(OC[C@]3(O)[C@](O)([2H])C([2H])([2H])N(C4=C(F)C=C(Cl)C=C4F)C([2H])([2H])C3([2H])[2H])=CC=C2F)CC1

Molecular Formula

C21H13D7ClF3N2O4

Molecular Weight

463.89

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64 (6) :e02020-19.